Baxter’s cardiovascular medicine eptifibatide approved by FDA

Baxter announced the FDA approval and launch of ready-to-use eptifibatide. Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells-from sticking together and clotting. Eptifibatide is indicated for medical treatment of acute coronary syndrome, a broad term that includes heart attack and other emergency conditions in which the blood supply to the heart is suddenly stopped. Eptifibatide is also indicated for treatment of patients undergoing percutaneous coronary intervention, in which physicians insert a catheter to visualize and open blocked coronary arteries and may, if needed, implant a mesh tube, called a stent, to keep the artery open. Eptifibatide uses Baxter’s proprietary Galaxy container technology. Eptifibatide is currently available from Baxter in the U.S.
https://thefly.com/landingPageNews.php?id=2875075